Duchenne Muscular Dystrophy (DMD) Therapeutics Growth Trajectory: Key Forecasts and Strategic Insights
Discover trends, market shifts, and competitive outlooks for the duchenne muscular dystrophy (dmd) therapeutics industry through 2025-2034 with The Business Research Company’s reliable data and in-depth research
What is the Anticipated CAGR of the Duchenne Muscular Dystrophy (DMD) Therapeutics Market, and What Factors Will Drive It?
The market size for Duchenne Muscular Dystrophy (DMD) therapeutics has seen a significant increase in the past few years. It is projected to expand from $11.95 billion in 2024 to $16.45 billion in 2025, exhibiting a compound annual growth rate (CAGR) of 37.6%. The remarkable growth noted during the historic period is due to the increasing incidence of Duchenne Muscular Dystrophy, heightened awareness about DMD treatments, increments in healthcare expenditures, and government actions.
In the coming years, the duchenne muscular dystrophy (DMD) therapeutics market is poised to experience significant escalation. Its growth is anticipated to reach $47.34 billion in 2029, with a compound annual growth rate (CAGR) of 30.3%. The projected growth within this period can be ascribed to an increase in investments for DMD treatments, the uptake of combined therapies, the advent of biomarkers, and an increase in screening programs for the disorder. The forecast period will witness trends such as innovative DMD treatments, the development of targeted therapies, the launch of new medications and remedies, and the introduction of unique disease-altering therapies, and vigorous drug developments.
Download a free sample to assess the report’s scope and structure:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12916&type=smp
Which Factors and External Forces Are Driving Demand in the Duchenne Muscular Dystrophy (DMD) Therapeutics Market?
The Duchenne muscular dystrophy (DMD) therapeutics market is expected to be driven by the growing number of clinical trials. These trials, which are medical studies carried out on human subjects, assess the safety and efficacy of novel medical interventions, treatments, or drugs. The increasing focus on clinical trials for Duchenne muscular dystrophy treatment underlines the ongoing research, innovation, and the plethora of therapeutic options. These factors could improve patient results, draw capital, and speed the development and availability of effective Duchenne muscular dystrophy therapies. For instance, The National Institutes Of Health (NIH), a US-based governmental agency for medical research, noted in August 2023 that registered clinical trials had risen to 464,218 from 399,496 in 2021 across all 50 United States and 221 countries. Also, around 142,700 studies (31% of the total) are registered in the U.S., while 248,310 studies (53% of the total) are noted in non-U.S. locations. Thus, the growing number of clinical trials is expected to bolster the Duchenne muscular dystrophy (DMD) therapeutics market’s growth. A major driver propelling the Duchenne Muscular Dystrophy (DMD) market is the increasing occurrence of genetic disorders. Genetic disorders are medical conditions caused by defects or mutations in a person’s DNA or genetic material. The rising incidence of these disorders places a larger population at potential risk of DMD due to genetic anomaly or inherited genetic profiles, driving a greater necessity for diagnostics, treatments, and therapeutics related to DMD. For example, the World Health Organization (WHO) reported that in February 2022, birth defects led to the demise of 240,000 newborns within the first 28 days of life annually. Additionally, another 170,000 children aged from 1 month to 5 years succumb to birth defects, including heart malformations, neural tube flaws, and Down syndrome. As a result, the escalating prevalence of genetic disorders is fueling the growth of the Duchenne muscular dystrophy (DMD) market.
Which Segments in the Duchenne Muscular Dystrophy (DMD) Therapeutics Offer the Most Growth?
The duchenne muscular dystrophy (DMD) therapeutics market covered in this report is segmented –
1) By Type: Small Molecules, Biologics
2) By Distribution Channel: Offline, Online
3) By Application: Hospitals, Clinics, Home Care
Subsegments:
1) By Small Molecules: Exon Skipping Therapies, Antisense Oligonucleotides, Read-Through Compounds
2) By Biologics: Gene Therapies, Cell Therapies, Protein Replacement Therapies
Request customized data on this market:
https://www.thebusinessresearchcompany.com/customise?id=12916&type=smp
What Are the Fastest-Growing Geographies in the Duchenne Muscular Dystrophy (DMD) Therapeutics Market?
North America was the largest region in the DMD therapeutics market in 2024. The regions covered in duchenne muscular dystrophy (DMD) therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
Which Cutting-Edge Market Trends Are Expected to Drive theDuchenne Muscular Dystrophy (DMD) Therapeutics Market’s Growth?
Leading enterprises in the Duchenne Muscular Dystrophy (DMD) therapeutics market are incorporating innovative techniques to boost the effectiveness and availability of DMD treatments, thereby reinforcing their foothold in the market. For example, in July 2023, Bit Bio Ltd., a synthetic biology organization from the UK, introduced disease model products to propel the progression of Duchenne muscular dystrophy (DMD) treatments. These disease models, called ioSkeletal Myocytes DMD Exon 44 Deletion and ioSkeletal Myocytes DMD Exon 52 Deletion, are human skeletal myocytes with genetically engineered deletions in the dystrophin protein production gene. These models, reprogrammed from induced pluripotent stem cells (iPSCs), offer a reliable and expandable source of human cells for research, tackling issues related to variability and the procurement of primary cells. These models facilitate the creation of treatments for DMD, contributing to understanding of disease mechanisms and viable treatments. This technological progress may speed up the efforts of researchers in finding potent treatments for DMD.
View the full report here:
What Are the Key Elements That Define the Duchenne Muscular Dystrophy (DMD) Therapeutics Market?
Duchenne muscular dystrophy (DMD) therapeutics refers to the various medical treatments and interventions aimed at managing and alleviating the symptoms of duchenne muscular dystrophy, a genetic disorder characterized by progressive muscle weakness and degeneration. These therapeutic approaches are designed to slow disease progression, improve muscle function and enhance the overall quality of life for individuals with duchenne muscular dystrophy.
Purchase the full report and get a swift delivery:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=12916
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
